Search results for Emibetuzumab
Emibetuzumab Biosimilar – Anti-MET, RCCP2 mAb – Research Grade, ProteoGenix, PX-TA1351
Description of Emibetuzumab Biosimilar - Anti-MET, RCCP2 mAb - Research Grade Introduction Emibetuzumab Biosimilar, also known as Anti-MET, RCCP2 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancers. This biosimilar is designed to target the MET receptor, which is overexpressed in many cancer types and plays a crucial role in tumor growth and progression. In this article, we will discuss the structure, activity, and potential applications of Emibetuzumab Biosimilar as a research-grade antibody. Structure of Emibetuzumab Biosimilar Emibetuzumab Biosimilar is a recombinant, humanized monoclonal antibody that is produced in mammalian cells. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding Fab regions at the end of the arms and a constant Fc region at the base. The Fab regions are responsible for binding to the MET receptor, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Emibetuzumab Biosimilar The main target of Emibetuzumab Biosimilar is the MET receptor, a tyrosine kinase receptor that is activated by its ligand, hepatocyte growth factor (HGF). Overexpression of MET has been observed in various cancers, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer, and is associated with poor prognosis and resistance to treatment. Emibetuzumab Biosimilar binds to the extracellular domain of MET and blocks its activation by HGF, thereby inhibiting downstream signaling pathways that promote tumor growth and metastasis. In addition to its direct anti-tumor activity, Emibetuzumab Biosimilar has been shown to enhance the effectiveness of other anti- cancer therapies. Studies have demonstrated that the combination of Emibetuzumab Biosimilar with chemotherapy or other targeted therapies can lead to improved tumor regression and prolonged survival in animal models. This is thought to be due to the ability of Emibetuzumab Biosimilar to sensitize cancer cells to the effects of other treatments by inhibiting the MET signaling pathway. Applications of Emibetuzumab Biosimilar Emibetuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various types of cancer, including renal cell carcinoma, non-small cell lung cancer, and gastric cancer. As a research-grade antibody, it is also widely used in preclinical studies to investigate the role of the MET receptor in cancer biology and to assess the potential of Emibetuzumab Biosimilar as a therapeutic agent. In addition to its potential as a monotherapy, Emibetuzumab Biosimilar is being studied in combination with other anti- cancer therapies. This includes combinations with chemotherapy, immune checkpoint inhibitors, and other targeted therapies. The goal of these studies is to identify the most effective treatment regimens for different types of cancer and to improve patient outcomes. Conclusion In summary, Emibetuzumab Biosimilar is a promising research-grade antibody that has the potential to be a valuable therapeutic agent for various types of cancer. Its unique mechanism of action, targeting the MET receptor, makes it a promising candidate for both monotherapy and combination therapy approaches. Ongoing clinical trials will provide further insights into the efficacy and safety of Emibetuzumab Biosimilar, and its potential to improve outcomes for cancer patients.
Host
Reactivity
Applications
Conjugation
Emibetuzumab, Abbexa, abx831310
Emibetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MET/RCCP2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Emibetuzumab ELISA Kit, ProteoGenix, KPTX163
Description of Emibetuzumab ELISA Kit Introduction to Emibetuzumab ELISA Kit Emibetuzumab is a monoclonal antibody that has shown promising results in the treatment of various types of cancer. It specifically targets the c-Met protein, which is overexpressed in many types of cancer and plays a crucial role in tumor growth and metastasis. The Emibetuzumab ELISA Kit is a powerful tool that allows for the detection and measurement of Emibetuzumab in biological samples, providing valuable information for researchers and clinicians. Structure of Emibetuzumab Emibetuzumab is a fully human IgG1 monoclonal antibody, meaning it is derived from human cells and has a constant region of the IgG1 isotype. This structure is important as it allows for a longer half-life in the body and a stronger binding affinity to its target, c-Met. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, each with a variable region that specifically binds to c-Met. Activity of Emibetuzumab The main activity of Emibetuzumab is its ability to bind to c-Met and inhibit its function. c-Met is a receptor tyrosine kinase that is activated by its ligand, hepatocyte growth factor (HGF), and plays a crucial role in cell growth, survival, and migration. Overexpression of c-Met has been linked to tumor growth, invasion, and metastasis in various types of cancer. By binding to c-Met, Emibetuzumab blocks the binding of HGF and prevents the activation of downstream signaling pathways, ultimately inhibiting tumor growth and metastasis. In addition to its inhibitory effects on c-Met, Emibetuzumab also has other mechanisms of action that contribute to its anti-tumor activity. It has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of tumor cells. Emibetuzumab also has the ability to block the formation of new blood vessels, known as angiogenesis, which is essential for tumor growth and survival. Application of Emibetuzumab ELISA Kit The Emibetuzumab ELISA Kit is a valuable tool for researchers and clinicians studying the use of Emibetuzumab in cancer treatment. It allows for the detection and measurement of Emibetuzumab in various biological samples, such as serum, plasma, and tissue lysates. This information can be used to monitor the levels of Emibetuzumab in patients undergoing treatment and to assess the efficacy of the therapy. The Emibetuzumab ELISA Kit can also be used in preclinical studies to determine the pharmacokinetics and pharmacodynamics of Emibetuzumab, providing valuable information for the development of new treatment strategies. Furthermore, the kit can be used to screen for potential drug-drug interactions and to assess the immunogenicity of Emibetuzumab in patients. Conclusion The Emibetuzumab ELISA Kit is a powerful tool for the detection and measurement of Emibetuzumab in biological samples. Its use in research and clinical settings allows for a better understanding of the structure, activity, and application of Emibetuzumab in cancer treatment. With its ability to specifically target c-Met and inhibit its function, Emibetuzumab shows great potential as a therapeutic antibody for various types of cancer. Ongoing studies and clinical trials will continue to explore the full potential of Emibetuzumab in the fight against cancer.
Host
Reactivity
Applications
Conjugation
Emibetuzumab ELISA Kit, Abbexa, abx395052
Emibetuzumab ELISA Kit is a quantitative ELISA kit for detection of Emibetuzumab.Emibetuzumab (as known as LY2875358) is a humanized immunoglobulin G4 monoclonal bivalent anti-MET antibody that blocks MET signaling. This drug was developed by Eli Lilly & Company and has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. In preclinical models, emibetuzumab inhibited growth of tumors that are dependent on MET, including tumors that exhibit HGF-dependent and HGF-independent biology. Administration of a single dose of emibetuzumab resulted in continuous reduction of MET protein expression for 14 days in mouse xenografts. Emibetuzumab demonstrated dose-dependent, single-agent activity in various MET-expressing tumor models, and additive effects were observed in combination with erlotinib for reducing tumor volume in lung cancer mouse xenograft models. In Phase 1 dose escalation studies, emibetuzumab monotherapy was well tolerated in patients with advanced solid tumors, including gastric cancer, with no dose-limiting toxicities.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Emibetuzumab Biosimilar - Research Grade, ichor.bio, ICH5148
Detects human MET
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.